• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/18/21 10:54:46 AM ET
    $CLBS
    Managed Health Care
    Health Care
    Get the next $CLBS alert in real time by email
    SC 13G 1 p21-0766sc13g.htm CALADRIUS BIOSCIENCES, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.   )*
     

    Caladrius Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001

    (Title of Class of Securities)
     

    128058203

    (CUSIP Number)
     

    February 12, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 10 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 128058203

    13GPage 2 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.90% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 128058203

    13GPage 3 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.90% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

     

    CUSIP No. 128058203

    13GPage 4 of 10 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,448,980 shares of Common Stock

    2,505,367 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.90% (See Item 4)*

    12

    TYPE OF REPORTING PERSON

    IN

             

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    CUSIP No. 128058203

    13GPage 5 of 10 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Caladrius Biosciences, Inc. (the "Company").
    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, New Jersey 07920.
    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to the Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i)        Empery Asset Management, LP (the "Investment Manager"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds").
       
      Reporting Individuals
       
      (ii)       Mr. Ryan M. Lane ("Mr. Lane"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      (iii)      Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
       
    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is:
       
     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    Item 2(c). CITIZENSHIP:

     

      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    CUSIP No. 128058203

    13GPage 6 of 10 Pages

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 (the "Common Stock")

     

    Item 2(e). CUSIP NUMBER:
       
      128058203

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) ¨ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                           

     

     

    CUSIP No. 128058203

    13GPage 7 of 10 Pages

     

    Item 4. OWNERSHIP.

     

        The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 58,434,763 shares of Common Stock issued and outstanding as of February 12, 2021, as represented in the Company’s Prospectus Supplement on Form 424(b)(5) filed with the Securities and Exchange Commission on February 16, 2021 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”) subject to the Blockers (as defined below).
         
        Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the Reported Warrants due to the Blockers.
         
        The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants (subject to the Blockers) held by, the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.
       
    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2(a) above.
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.  

     

    CUSIP No. 128058203

    13GPage 8 of 10 Pages

     

      Not applicable.
       
    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
       
    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 128058203

    13GPage 9 of 10 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 18, 2021

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
         
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
       /s/ Ryan M. Lane
      Ryan M. Lane
       
       /s/ Martin D. Hoe
      Martin D. Hoe

     

     

     

     

    CUSIP No. 128058203

    13GPage 10 of 10 Pages

     

    EXHIBIT 1

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: February 18, 2021

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
         
      By: /s/ Ryan M. Lane
      Name:  Ryan M. Lane
      Title:  Managing Member
       
       /s/ Ryan M. Lane
      Ryan M. Lane
       
       /s/ Martin D. Hoe
      Martin D. Hoe

     

     

     

     

     

     

    Get the next $CLBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CLBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

      Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius") and Cend Therapeutics, Inc. ("Cend") today announced that the proposed merger of the two companies has closed following the approval of Caladrius' stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc.

      9/15/22 9:15:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

      BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 26, 2022, by and among Caladrius and Cend Therapeutics ("Cend"), and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius' common stock to Cend's stockholders pursuant to the Agreement and Plan of Merge

      9/14/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

      BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York City (Hybrid conference)Presentation format: In-person and live/archived webcastPresentation Date/Time: Wednesday, September 14, 2022, at 12:00 p.m. ESTWebcast Link: https://bit.ly/3ARcXnjFor m

      9/8/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors

      MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the appointment of Todd Girolamo to its Board of Directors. Girolamo is a seasoned attorney and biopharmaceutical executive specializing in health-related products, currently serving as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary for Caladrius Biosciences, Inc. (NASDAQ:CLBS). "Mr. Girolamo will bring invaluable legal, finance and biopharmaceutical development insight and leadership to our Board," said

      2/17/22 8:00:00 AM ET
      $CLBS
      $LGVN
      Managed Health Care
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

      BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company's Chief Medical Officer ("CMO"). Dr. Buck joins Caladrius from ICON plc ("ICON"), a global provider of drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. During her time at ICON, Dr. Buck served as its CMO, where she represented the company's position on key scientific, ethical, and medical govern

      9/1/21 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

      NEW YORK, Dec. 2, 2020 /PRNewswire/ -- HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer. "We're pleased to welcome Joe to the HiberCell team and have Ari take on an expanded role as chief business officer," said Alan C. Rigby, Ph.D., co-founder and chief executive officer of HiberCell. "Joe has a track record of successful financial leadership and we're pleased to have him on board during a tremendous period of organizational growth. As a co-founder o

      12/2/20 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      2/14/22 3:27:23 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      2/10/22 3:46:07 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Caladrius Biosciences Inc. (Amendment)

      SC 13G/A - CALADRIUS BIOSCIENCES, INC. (0000320017) (Subject)

      1/19/22 10:44:54 AM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Financials

    Live finance-specific insights

    See more
    • Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our

      8/4/22 4:05:00 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

      BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT). The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid d

      7/28/22 8:00:00 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

      Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Management will host a conference call tomorrow, May 24th at 8:15 a.m. EDT BASKING RIDGE, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company has suspended patient enrollment in its Phase 2b study of XOWNA®, known as

      5/23/22 4:05:00 PM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/17/23 5:05:25 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/12/23 4:02:08 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form 4: Ruoslahti Erkki was granted 20,000 shares

      4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

      1/11/23 4:20:29 PM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Caladrius Biosciences Inc.

      10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      11/10/22 4:12:58 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • Caladrius Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      11/10/22 4:10:40 PM ET
      $CLBS
      Managed Health Care
      Health Care
    • SEC Form S-8 filed by Caladrius Biosciences Inc.

      S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

      10/17/22 4:02:44 PM ET
      $CLBS
      Managed Health Care
      Health Care

    $CLBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital Management reiterated coverage on Caladrius Biosciences with a new price target

      Brookline Capital Management reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/9/21 8:09:13 AM ET
      $CLBS
      Managed Health Care
      Health Care
    • Brookline Capital reiterated coverage on Caladrius Biosciences with a new price target

      Brookline Capital reiterated coverage of Caladrius Biosciences with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/3/21 12:13:10 PM ET
      $CLBS
      Managed Health Care
      Health Care